TMEM179 Inhibitors
Inhibitors targeting TMEM179 function by modulating various cellular processes and signaling pathways to ultimately reduce the activity of this transmembrane protein. One class of inhibitors acts by hindering the mTOR pathway, which is essential for cell growth and protein stability; interference with this pathway can lead to decreased trafficking or stability of TMEM179. Another approach involves the disruption of calcium homeostasis through the inhibition of Ca2+ ATPases, which affects the conformation and trafficking of TMEM179. Additionally, compounds that inhibit the V-ATPase proton pump can alter endosomal processing, potentially leading to the mislocalization and functional impairment of TMEM179. Similarly, the use of actin polymerization inhibitors destabilizes cytoskeletal dynamics, which is critical for the correct localization and function of such membrane proteins.
Furthermore, TMEM179 function can be indirectly inhibited by compounds that interfere with protein phosphorylation and dephosphorylation. Inhibitors of calcineurin prevent the activation of proteins that might be involved in the degradation or mislocalization of TMEM179. Proteasome inhibitors contribute to the accumulation of polyubiquitinated proteins, which may indirectly reduce TMEM179 turnover and function. Glycosylation inhibitors can affect TMEM179 by disrupting its proper folding and membrane trafficking, leading to a loss of function. Additionally, inhibitors of kinases such as NUAK family kinases and MEK can alter signaling pathways and downstream proteins that could indirectly modify the phosphorylation status or stability of TMEM179, ultimately diminishing its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This macrolide compound inhibits mTOR, which is a kinase involved in cell growth and proliferation. Inhibition of mTOR leads to reduced activity of downstream effectors, including those that may regulate the trafficking or stability of TMEM179 in cells. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
This compound inhibits calcineurin. Given that calcineurin dephosphorylates numerous proteins, its inhibition may prevent the dephosphorylation and subsequent activation of proteins that could degrade or mislocalize TMEM179. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
This selective NUAK family kinase inhibitor can impede cellular processes regulated by these kinases, thereby potentially altering the phosphorylation status of TMEM179 or its interacting partners, resulting in decreased TMEM179 function. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
This compound specifically inhibits the V-ATPase proton pump, disrupting endosomal acidification. TMEM179, being a transmembrane protein, could be affected by altered endosomal processing, leading to its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can lead to the accumulation of polyubiquitinated proteins. This accumulation might affect the degradation pathway of TMEM179, potentially reducing its turnover and function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
An N-glycosylation inhibitor that can disrupt the glycosylation of membrane proteins, potentially affecting the proper folding and trafficking of TMEM179 to the membrane, leading to its functional inhibition. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to disruption of calcium homeostasis. Perturbed Ca2+ signaling could affect the conformation or trafficking of TMEM179. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A dynamin inhibitor, which may disrupt endocytosis and vesicle trafficking processes. Such disruption could impede the proper localization of TMEM179, thus inhibiting its function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
An actin polymerization inhibitor that can disrupt cytoskeletal dynamics. Since the cytoskeleton is involved in the trafficking and localization of membrane proteins, TMEM179 could be functionally inhibited by improper localization. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that interferes with the MAPK/ERK pathway. As this pathway is involved in numerous cellular processes, including protein trafficking and stability, it could indirectly affect the function of TMEM179. | ||||||